Intel’s Comeback Rally; AI Tools Go No-Code; Apple Takes on Adobe; and the GLP-1 Reality Check

Dipo Owolabi
Jan 15
4 min read

15th January 2025

Intel shares are surging again, up 28% this year as analysts raise price targets on stronger chip demand and growing confidence in the company’s manufacturing comeback. In artificial intelligence, Anthropic is pushing AI beyond engineers with its new Cowork tool, while Apple moves directly against Adobe by bundling its creative software into a new Creator Studio subscription aimed at locking in professional creators. And in healthcare, fresh research suggests the weight-loss gains from GLP-1 drugs like Ozempic may fade within 18 months after stopping treatment, reigniting debate over whether the blockbuster medications are a long-term solution or a lifelong commitment. All this and more in today’s Read It And Eat!

Major Headlines

Intel’s Quiet Comeback kicks into High Gear

Intel shares have climbed 28% year-to-date, extending a strong rebound from last year as analysts grow more confident in the company’s turnaround strategy. Banks including KeyBanc and UBS raised their price targets, pointing to stronger-than-expected demand for server processors and early traction in Intel’s foundry business. The rally marks a sharp shift in sentiment after years of skepticism around Intel’s competitiveness.

Investors are responding to signs that Intel is stabilizing its core data-center business while positioning itself as a manufacturing alternative to Asian chipmakers. Growing demand for AI-adjacent infrastructure, even outside Nvidia’s ecosystem, has helped reframe Intel as a beneficiary of broader compute expansion rather than a laggard in the AI race.

Still, analysts caution that execution risks remain high. Intel’s long-term valuation depends on its ability to scale foundry services, control costs, and deliver next-generation chips on schedule, a challenge that will determine whether the rally has staying power or proves premature. Technobezz

Anthropic's new Cowork tool offers Claude Code without the code

Anthropic has unveiled Cowork, a new tool designed to bring Claude’s advanced coding capabilities to non-technical users. Available to Claude Max subscribers on macOS, Cowork positions itself as “Claude Code for the rest of your work,” allowing users to automate tasks, analyze documents, and build workflows without writing code.

The launch reflects a broader shift in AI development: moving from tools designed for engineers to products aimed at knowledge workers. By lowering technical barriers, Anthropic is betting that productivity gains will come not just from developers, but from professionals across business, research, and creative industries.

Cowork also intensifies competition in the enterprise AI space, where ease of use is becoming as important as model performance. As AI tools spread beyond technical teams, questions around data privacy, accuracy, and organizational reliance on AI systems are becoming increasingly urgent. Techradar

Apple aims to take on Adobe with its new Creator Studio suite

Apple is launching its new Creator Studio suite on January 28, bundling its flagship creative tools into a single subscription priced at $13 per month or $129 per year. The package includes Final Cut, Logic, Pixelmator Pro, Motion, Compressor, and MainStage, positioning Apple as a direct competitor to Adobe’s Creative Cloud for professional creators.

Several of the apps including Final Cut, Logic, and Pixelmator Pro will run across both Mac and iPad, reinforcing Apple’s push toward cross-device creative workflows. However, Motion, Compressor, and MainStage remain Mac-only, underscoring Apple’s continued emphasis on high-performance desktop creation. The move signals Apple’s intent to keep creators locked into its hardware ecosystem rather than chasing platform-agnostic distribution.

Despite the new bundle, Apple will continue selling many of its creative apps individually, with Final Cut priced at $300, Logic at $200, and Pixelmator Pro at $50. That dual strategy allows Apple to attract new creators with a low monthly entry point while preserving high-margin one-off purchases for professionals a model that could pressure Adobe as subscription fatigue grows among creatives. MSN

Studies Show Ozempic Users Regain Lost Weight in just 18 months

A new analysis suggests that people who stop taking GLP-1 weight-loss drugs such as Ozempic and Wegovy typically regain the weight they lost within about 18 months. The findings challenge the idea that these medications offer a permanent solution to obesity without long-term use.

The results highlight a central tension in the GLP-1 boom: while the drugs are highly effective at suppressing appetite, their benefits appear to fade once treatment ends. This raises questions about cost, access, and whether lifelong use is realistic or desirable for patients.

For healthcare systems and insurers, the findings complicate coverage decisions. As GLP-1 drugs reshape weight-loss medicine, policymakers and clinicians must grapple with whether they represent a chronic treatment model and how to manage expectations around long-term outcomes. Washington Post

Minor Headlines